European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Home
/
update
/
details

Biognosys and Thermo Fisher Sign Reselling Agreement for Spectronaut Proteomics Software

NextEdge Admin

19 Sep 2024

2 min 11 sec

Biognosys has announced a reselling agreement with Thermo Fisher Scientific for its Spectronaut proteomics software. As part of the partnership, the two companies will comarket and sell Spectronaut, which is specifically designed for data-independent acquisition (DIA) proteomics experiments.

The agreement grants Thermo Fisher the right to quote and sell Spectronaut directly from its product catalog. This enables customers to purchase both a Thermo Fisher mass spectrometry system and the Spectronaut software as part of a single, streamlined package.

Although financial details of the agreement were not disclosed, the collaboration is expected to enhance accessibility to Spectronaut for users of Thermo Fisher’s mass spectrometry instruments. Oliver Rinner, CEO and founder of Biognosys, emphasized the importance of data analysis in mass spectrometry-based proteomics, noting that the partnership will help advance the DIA acquisition method, a cutting-edge approach in discovery proteomics. He also highlighted the value of cross-platform comparability in accelerating progress in the emerging field of proteomics.

August Specht, Vice President of R&D for chromatography and mass spectrometry at Thermo Fisher, echoed these sentiments. He expressed enthusiasm for the collaboration, stating that combining Spectronaut with Thermo Fisher’s mass spectrometry systems will offer researchers a powerful, integrated solution for DIA proteomics workflows.

This partnership is expected to provide a comprehensive solution for researchers, facilitating more efficient proteomics research across different platforms.